Učitavanje...
Cognitive evolution in natalizumab-treated multiple sclerosis patients
BACKGROUND: Cognitive dysfunction affects up to 65% of multiple sclerosis (MS) patients and progresses over time. Natalizumab has been shown to be superior to placebo in preserving cognition for the first two years of therapy. OBJECTIVES: The objectives of this study are to understand the impact of...
Spremljeno u:
| Izdano u: | Mult Scler J Exp Transl Clin |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5408753/ https://ncbi.nlm.nih.gov/pubmed/28607732 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217316657116 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|